regorafenib vs sorafenib in the treatment of liver cancer
Published 8 years ago • 1.3K plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:10
real life analysis shows regorafenib improves survival upon progression on sorafenib in hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
3:06
dr. finn on tivantinib and regorafenib for the treatment of liver cancer
-
3:11
regorafenib in advanced hcc
-
3:02
using sorafenib in advanced hcc
-
1:27
dr. sherman on the role of regorafenib in liver cancer
-
1:07
recent advancements for the treatment of liver cancer
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
1:09
survival benefit confirmed in real-life analysis of second-line regorafenib in hcc
-
58:25
molecular targeted therapies for advanced hcc
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
1:28
surivival benefit of regorafenib in correct and concur trials
-
6:02
hcc: considerations in first-line use of sorafenib
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
0:49
dr. daniele on impact of regorafenib in hcc
-
4:33
managing systemic treatment in liver cancer
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
1:51
managing side effects with regorafenib in hcc
-
5:40
sorafenib initiation after tace in hcc